Adamis Pharmaceuticals investor relations material
Listen to the latest call from Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company is focused on developing and commercializing products in the therapeutic areas of allergy, opioid overdose and respiratory disease. The company's product candidate includes Symjepi (previously known as APC-5000), an epinephrine syringe for self-administration by patients for emergency treatment of acute allergic reactions, including anaphylaxis. It is designed to be prefilled and ready to use immediately at the time of need. The Company's sales channels include the Pulmonary Division of Forest Laboratories, Inc., which markets Symjepi to wholesalers exclusively in the U.S.